Top
Topic: Drug resistance and cancer stem cell

A special issue of Cancer Drug Resistance.

ISSN 2578-532X (Online)

Submission deadline: 31 Aug 2019

Guest Editor(s)

  • Dr. Miroslav Blumenberg
    The RO Perelman Department of Dermatology, Department of Biochemistry and Molecular Pharmacology, NYU School of Medicine, NY, USA.

    Website | E-mail

Special Issue Introduction

Both solid tumors as well as leukemias and lymphomas depend for their proliferation on a small group of progenitor cells, the cancer stem cells. These are tumorigenic and both self-renew and generate more differentiated, non-tumorigenic cells. The cancer stem cells are responsible for metastases, as well as for the post-therapeutic relapses of tumors. Therefore there is a great interest and importance in identifying and, if possible, specifically targeting the cancer stem cells. Recent developments in single cell omics approaches hold great promise in this regard.
The special issue on “Cancer Stem Cells” will include Original Articles, Reviews and Commentaries, etc. updating the current state of knowledge and clinical uses of identifying and targeting cancer stem cells. The special issue will also include Research articles presenting novel outstanding data on all aspects of cancer stem cell-targeted therapies. All submissions will undergo rigorous peer review and will be published free of charge upon acceptance.

Keywords

Biomarkers, Differentiation therapy, Metastasis, Omics, Relapse, Single cell studies, Stemness.

Submission Deadline

31 Aug 2019

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to http://cdrjournal.com/pages/view/author_instructions
For Online Submission, please login at http://www.oaemesas.com/cdr
Submission Deadline: 31 Aug 2019
Contacts: Elaine Gao, Managing Editor, editorial@cdrjournal.com
                  Ellie Liang, Editor, ellie.liang@oaepublish.com

Planned Papers

Type: Review

Title: The mechanism and regulation of epithelial-mesenchymal transition in cancer stem cells

Authors: Shihori Tanabe1), Sabina Quader2), Horacio Cabral3), Ryuichi Ono4)

Affiliations: 1)Division of Risk Assessment, Center for Biological Safety and Research, National Institute of Health Sciences
2)Innovation Centre of NanoMedicine (iCONM)
3)Department of Bioengineering, Graduate School of Engineering, The University of Tokyo
4)Division of Toxicology, Center for Biological Safety and Research, National Institute of Health Sciences

Abstract: The mechanism of epithelial-mesenchymal transition (EMT) consists of cellular phenotypic transition from epithelial to mesenchymal status. The cells exhibiting EMT exist in cancer stem cell (CSC) population, which is involved in drug resistance. The signaling pathways are dynamically regulated by microRNAs in EMT and CSCs. The recent progress in nano molecules has arisen the possibility to target CSCs with nano-particles. In this review article, we focused on the mechanism of CSCs and EMT, especially into the signaling pathways in EMT, regulation of EMT and CSCs by microRNAs and nano-particles.


Type: Review

Title: Current therapeutics targeting breast cancer stem cells

Authors: Dong-Xu Liu et al.

Affiliations: Auckland University of Technology, New Zealand.

Abstract: Cancer stem cells are believed to drive tumour initiation, progression and metastasis, and confer resistance to radiation and chemotherapy. Cancer stem cells-targeting has been shown to be a promising strategy for the management and eradication of many types of cancers. There are currently a number of agents that target breast cancer stem cells in preclinical models and in clinical trials. The review will summarise the most recent development of these potential therapeutics and discuss the limitations and challenges.


Published Articles